HK1156624A1 - Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor hcv 2--4-- - Google Patents
Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor hcv 2--4--Info
- Publication number
- HK1156624A1 HK1156624A1 HK11111031.5A HK11111031A HK1156624A1 HK 1156624 A1 HK1156624 A1 HK 1156624A1 HK 11111031 A HK11111031 A HK 11111031A HK 1156624 A1 HK1156624 A1 HK 1156624A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hcv
- quinolinyl
- thiazolyl
- crystalline forms
- potent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9729108P | 2008-09-16 | 2008-09-16 | |
| US15082609P | 2009-03-09 | 2009-03-09 | |
| PCT/US2009/056772 WO2010033444A1 (en) | 2008-09-16 | 2009-09-14 | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1156624A1 true HK1156624A1 (en) | 2012-06-15 |
Family
ID=41268627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK11111031.5A HK1156624A1 (en) | 2008-09-16 | 2011-10-17 | Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor hcv 2--4-- |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US8232293B2 (me) |
| EP (2) | EP2331538B1 (me) |
| JP (2) | JP5520301B2 (me) |
| KR (1) | KR101653550B1 (me) |
| CN (1) | CN102159571B (me) |
| AR (1) | AR073298A1 (me) |
| AU (1) | AU2009293494B2 (me) |
| BR (1) | BRPI0918513A2 (me) |
| CA (1) | CA2737055C (me) |
| CL (1) | CL2011000558A1 (me) |
| CO (1) | CO6351741A2 (me) |
| CY (1) | CY1115253T1 (me) |
| DK (1) | DK2331538T3 (me) |
| EA (1) | EA018603B1 (me) |
| EC (1) | ECSP11010878A (me) |
| ES (1) | ES2474992T3 (me) |
| HK (1) | HK1156624A1 (me) |
| HR (1) | HRP20140666T1 (me) |
| IL (1) | IL210345A (me) |
| MA (1) | MA32633B1 (me) |
| ME (1) | ME01831B (me) |
| MX (1) | MX2011002828A (me) |
| MY (1) | MY153093A (me) |
| NZ (2) | NZ591013A (me) |
| PE (2) | PE20130307A1 (me) |
| PL (1) | PL2331538T3 (me) |
| PT (1) | PT2331538E (me) |
| RS (1) | RS53292B (me) |
| SG (1) | SG189740A1 (me) |
| SI (1) | SI2331538T1 (me) |
| TW (1) | TWI471323B (me) |
| UY (1) | UY32119A (me) |
| WO (1) | WO2010033444A1 (me) |
| ZA (1) | ZA201100096B (me) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| KR101653550B1 (ko) | 2008-09-16 | 2016-09-02 | 베링거 인겔하임 인터내셔날 게엠베하 | 강력한 ｈｃｖ 억제제인 2-티아졸릴-4-퀴놀리닐-옥시 유도체의 결정 형태 |
| WO2010033443A1 (en) | 2008-09-17 | 2010-03-25 | Boehringer Ingelheim International Gmbh | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
| US9522068B2 (en) * | 2009-03-13 | 2016-12-20 | The University Of Toledo | Minimally invasive collapsible cage |
| CA2753657A1 (en) * | 2009-03-19 | 2010-09-23 | Boehringer Ingelheim International Gmbh | Process for preparing sulfonyl quinolines |
| WO2010129451A1 (en) * | 2009-05-05 | 2010-11-11 | Boehringer Ingelheim International Gmbh | Process for preparing bromo-substituted quinolines |
| MY154683A (en) | 2009-07-07 | 2015-07-15 | Boehringer Ingelheim Int | Pharmaceutical composition for a hepatitis c viral protease inhibitor |
| NZ598465A (en) | 2009-10-30 | 2013-10-25 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
| US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
| AU2011310761A1 (en) * | 2010-09-30 | 2013-02-21 | Boehringer Ingelheim International Gmbh | Combination therapy for treating HCV infection |
| CN103534256B (zh) | 2010-12-30 | 2016-08-10 | 益安药业 | 大环丙型肝炎丝氨酸蛋白酶抑制剂 |
| WO2012092411A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc. | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| CH707029B1 (de) | 2011-10-21 | 2015-03-13 | Abbvie Inc | Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon. |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| AU2013201532B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| CN104244926A (zh) | 2012-01-12 | 2014-12-24 | 勃林格殷格翰国际有限公司 | 作为强效的hcv 抑制剂的稳定的药物制剂 |
| WO2013137869A1 (en) | 2012-03-14 | 2013-09-19 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
| WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
| WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| JP2015512900A (ja) | 2012-03-28 | 2015-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法 |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| ES2735355T3 (es) | 2013-03-15 | 2019-12-18 | Gilead Sciences Inc | Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C |
| US9732076B2 (en) * | 2013-03-15 | 2017-08-15 | Boehringer Ingelheim International Gmbh | Solid oral dosage formulation of HCV inhibitor in the amorphous state |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2022107182A1 (en) * | 2020-11-18 | 2022-05-27 | University Of Petra | A composition of fentanyl and fatty acids, and a method of preparation thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI0649651T1 (en) | 1993-09-28 | 2001-02-28 | Scherer Gmbh R P | Soft gelatin capsule manufacture |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| NZ519984A (en) * | 2000-01-07 | 2004-03-26 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| UY28240A1 (es) * | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
| MXPA05012545A (es) | 2003-05-21 | 2006-02-08 | Boehringer Ingelheim Int | Compuestos inhibidores de la hepatitis c. |
| US7514557B2 (en) | 2004-05-25 | 2009-04-07 | Boehringer Ingelheim International Gmbh | Process for preparing acyclic HCV protease inhibitors |
| KR101653550B1 (ko) * | 2008-09-16 | 2016-09-02 | 베링거 인겔하임 인터내셔날 게엠베하 | 강력한 ｈｃｖ 억제제인 2-티아졸릴-4-퀴놀리닐-옥시 유도체의 결정 형태 |
| US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
-
2009
- 2009-09-14 KR KR1020117004209A patent/KR101653550B1/ko active IP Right Grant
- 2009-09-14 SI SI200930919T patent/SI2331538T1/sl unknown
- 2009-09-14 PE PE2012002419A patent/PE20130307A1/es active IP Right Grant
- 2009-09-14 ME MEP-2014-43A patent/ME01831B/me unknown
- 2009-09-14 RS RS20140230A patent/RS53292B/en unknown
- 2009-09-14 NZ NZ591013A patent/NZ591013A/xx not_active IP Right Cessation
- 2009-09-14 MX MX2011002828A patent/MX2011002828A/es active IP Right Grant
- 2009-09-14 BR BRPI0918513A patent/BRPI0918513A2/pt not_active Application Discontinuation
- 2009-09-14 JP JP2011527015A patent/JP5520301B2/ja active Active
- 2009-09-14 EA EA201100482A patent/EA018603B1/ru not_active IP Right Cessation
- 2009-09-14 PT PT97924930T patent/PT2331538E/pt unknown
- 2009-09-14 NZ NZ602163A patent/NZ602163A/xx not_active IP Right Cessation
- 2009-09-14 MY MYPI20111140 patent/MY153093A/en unknown
- 2009-09-14 CN CN200980136131.XA patent/CN102159571B/zh not_active Expired - Fee Related
- 2009-09-14 SG SG2013024864A patent/SG189740A1/en unknown
- 2009-09-14 CA CA2737055A patent/CA2737055C/en not_active Expired - Fee Related
- 2009-09-14 ES ES09792493.0T patent/ES2474992T3/es active Active
- 2009-09-14 DK DK09792493.0T patent/DK2331538T3/da active
- 2009-09-14 WO PCT/US2009/056772 patent/WO2010033444A1/en active Application Filing
- 2009-09-14 PL PL09792493T patent/PL2331538T3/pl unknown
- 2009-09-14 EP EP09792493.0A patent/EP2331538B1/en active Active
- 2009-09-14 EP EP13188665.7A patent/EP2687526A1/en not_active Withdrawn
- 2009-09-14 AU AU2009293494A patent/AU2009293494B2/en not_active Ceased
- 2009-09-14 PE PE2011000636A patent/PE20110388A1/es not_active Application Discontinuation
- 2009-09-15 US US12/559,927 patent/US8232293B2/en active Active
- 2009-09-15 TW TW98131069A patent/TWI471323B/zh not_active IP Right Cessation
- 2009-09-15 UY UY0001032119A patent/UY32119A/es not_active Application Discontinuation
- 2009-09-15 AR ARP090103540A patent/AR073298A1/es not_active Application Discontinuation
-
2010
- 2010-12-29 IL IL210345A patent/IL210345A/en active IP Right Grant
-
2011
- 2011-01-04 ZA ZA2011/00096A patent/ZA201100096B/en unknown
- 2011-03-09 EC EC2011010878A patent/ECSP11010878A/es unknown
- 2011-03-14 MA MA33699A patent/MA32633B1/fr unknown
- 2011-03-16 CO CO11032830A patent/CO6351741A2/es not_active Application Discontinuation
- 2011-03-16 CL CL2011000558A patent/CL2011000558A1/es unknown
- 2011-10-17 HK HK11111031.5A patent/HK1156624A1/xx not_active IP Right Cessation
-
2012
- 2012-07-03 US US13/541,158 patent/US8362035B2/en active Active
-
2013
- 2013-12-09 JP JP2013253812A patent/JP2014062116A/ja not_active Withdrawn
-
2014
- 2014-07-11 CY CY20141100526T patent/CY1115253T1/el unknown
- 2014-07-14 HR HRP20140666AT patent/HRP20140666T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1156624A1 (en) | Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor hcv 2--4-- | |
| LT2155200T (lt) | Karbamoil-cikloheksano darinio kristalinė forma | |
| HK1205125A1 (en) | Polymorphic forms of a macrocyclic inhibitor of hcv hcv | |
| IL221123A (en) | Powerful polythrocyclic compounds as hcv inhibitors | |
| HK1200440A1 (zh) | 種抑制劑的結晶形式 | |
| GB0819182D0 (en) | Crystalline forms | |
| IL196706A0 (en) | Crystalline forms of rapamycin analogs | |
| IL221198A0 (en) | Crystalline salts of a potent hcv inhibitor | |
| HK1164698A1 (en) | Crystalline forms of genistein | |
| HK1124068A1 (en) | 2-arylindole derivatives as mpges-1 inhibitors | |
| SI2358676T1 (sl) | Kristalinična oblika 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine | |
| ZA201100999B (en) | Synthesis of a crystalline silicoaluminophosphate | |
| PL2343292T3 (pl) | Nowa pochodna prostaglandyny I<sub>2</sub> | |
| ZA200903614B (en) | New crystalline forms | |
| ZA201104319B (en) | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | |
| AP2013006733A0 (en) | Solid state forms of a potent HCV inhibitor | |
| IL210777A0 (en) | Crystalline forms of a pyridine derivative | |
| IL208543A (en) | History of the eupyrpine peptide as potent inhibitors of encephalin-actopeptidase joint | |
| EP1983997A4 (en) | CRYSTALLINE FORMS OF A FARNESYL DIBENZODIAZEPINONE | |
| ZA200900740B (en) | Crystalline forms of rapamycin analogs | |
| HU0800755D0 (en) | Novel crystalline forms | |
| IL213288A0 (en) | Crystalline forms | |
| GB0817164D0 (en) | Crystalline forms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210914 |